乐普医疗总经理蒲绯上任后首份年报：三大板块营收承压，净利下滑八成

Core Viewpoint - Lepu Medical (SZ300003) reported a significant decline in financial performance for the year 2024, with a notable drop in revenue and net profit compared to previous years [1][4]. Financial Performance Summary - The company achieved an operating revenue of 6.103 billion yuan in 2024, a decrease of 23.52% from 2023 [2]. - The net profit attributable to shareholders was 246.94 million yuan, down 80.37% year-on-year [2]. - The net profit after deducting non-recurring gains and losses was 221.43 million yuan, reflecting an 80.28% decline [2]. - The net cash flow from operating activities was 734.64 million yuan, a decrease of 25.82% compared to the previous year [2]. - Basic earnings per share were 0.1336 yuan, down 80.23% from 2023 [2]. Asset and Equity Summary - Total assets at the end of 2024 amounted to 24.573 billion yuan, a decrease of 1.80% from the end of 2023 [2]. - The weighted average return on equity was 1.59%, down 6.64 percentage points from the previous year [2]. Segment Performance - The medical device segment generated revenue of 3.326 billion yuan, down 9.47% year-on-year [4]. - The pharmaceutical segment reported revenue of 1.758 billion yuan, a decline of 42.25% [4]. - The medical services and health management segment achieved revenue of 1.019 billion yuan, down 19.24% [4]. Impairment Losses - The company recognized impairment losses totaling 251 million yuan, impacting net profit attributable to shareholders by 217 million yuan [4]. Management Changes - On September 24, 2024, the company appointed Pu Fei as the new General Manager, who is the daughter of the controlling shareholder [5].